Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma
Objectives. Although raltitrexed shows therapeutic effects in many types of malignant tumors, the therapeutic effects and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) loaded with raltitrexed for the treatment of hepatocellular carcinoma (HCC) are rare. This study aimed to i...
Saved in:
Main Authors: | Yonghua Bi, Dechao Jiao, Jianzhuang Ren, Xinwei Han |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Canadian Journal of Gastroenterology and Hepatology |
Online Access: | http://dx.doi.org/10.1155/2022/2602121 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Lethal Complication after Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma
by: Adriana Toro, et al.
Published: (2015-01-01) -
Conventional and drug‑eluting bead transarterial chemoembolization in patients with inoperable intrahepatic cholangiocarcinoma: a meta‑analysis
by: Su-Rong Pan, et al.
Published: (2024-11-01) -
TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma
by: Wang W, et al.
Published: (2025-01-01) -
Efficacy analysis of drug-eluting beads transcatheter arterial chemoembolization combining systemic chemotherapy and immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study based on propensity score matching
by: Liu Song, et al.
Published: (2025-01-01) -
Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
by: A. Rebonato, et al.
Published: (2017-01-01)